BACKGROUND: Smoking withdrawal and relapse were characterized among newly diagnosed head and neck cancer patients participating in a physician-delivered smoking cessation intervention. METHODS: Patients completed questionnaires at baseline, 1, 6, and 12 months following intervention delivery. RESULTS: Significant baseline predictors of smoking relapse included medical treatment (XRT versus surgical treatment), stage of change/readiness to quit (precontemplators), age of initiation (younger), and greater addiction (smoking </=30 minutes after waking). Relapsers were significantly more likely to quit using gradual reduction versus cold turkey and had less confidence in remaining quit. Relapsers experienced significantly higher levels of anxiety and craving during withdrawal. Relapse was temporally delayed compared with healthy populations. CONCLUSION: Assistance with cessation efforts should be ongoing for one year and should include nicotine replacement therapy and psychotropic medications to address significant relapse triggers. Copyright 1999 John Wiley & Sons, Inc. Head Neck 21: 420-427, 1999.
BACKGROUND: Smoking withdrawal and relapse were characterized among newly diagnosed head and neck cancerpatients participating in a physician-delivered smoking cessation intervention. METHODS:Patients completed questionnaires at baseline, 1, 6, and 12 months following intervention delivery. RESULTS: Significant baseline predictors of smoking relapse included medical treatment (XRT versus surgical treatment), stage of change/readiness to quit (precontemplators), age of initiation (younger), and greater addiction (smoking </=30 minutes after waking). Relapsers were significantly more likely to quit using gradual reduction versus cold turkey and had less confidence in remaining quit. Relapsers experienced significantly higher levels of anxiety and craving during withdrawal. Relapse was temporally delayed compared with healthy populations. CONCLUSION: Assistance with cessation efforts should be ongoing for one year and should include nicotine replacement therapy and psychotropic medications to address significant relapse triggers. Copyright 1999 John Wiley & Sons, Inc. Head Neck 21: 420-427, 1999.
Authors: Marie-Helene Gosselin; Martin C Mahoney; K Michael Cummings; Thom R Loree; Maureen Sullivan; Brian A King; Graham Warren; Andrew Hyland Journal: J Cancer Educ Date: 2011-09 Impact factor: 2.037
Authors: Erika Litvin Bloom; Jason A Oliver; Steven K Sutton; Thomas H Brandon; Paul B Jacobsen; Vani Nath Simmons Journal: Psychooncology Date: 2014-09-25 Impact factor: 3.894
Authors: Vani Nath Simmons; Erika B Litvin; Paul B Jacobsen; Riddhi D Patel; Judith C McCaffrey; Jason A Oliver; Steven K Sutton; Thomas H Brandon Journal: Cancer Date: 2012-12-20 Impact factor: 6.860